NBRV - Earnings call transcript Q4 2019 | Nabriva Therapeutics plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Nabriva Fourth Quarter 2019 Financial Results Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference maybe recorded.

I would now like to turn the conference over to your host, Mr. Officer. Financial Chief Sender, Gary

Gary Sender

Thank you, call and to conference everyone. year good webcast to afternoon, and quarter earnings. Welcome discuss XXXX Nabriva’s and the full fourth

conference to Before I’d company. to that These to forward-looking remind could call subject the and are and everyone statements we about webcast like differ. that risks begin, statements cause contain will results this uncertainties actual

forward-looking of these that statements the of note opinions as reflect Please only call. date this our

release future no the recent these actual undertake to that differ obligation to reports the revisions light or SEC. publicly could by and outcomes from forward-looking detail of discussed will to results We with forward-looking statements filings of revise any new expressed from events. X-K cause in XX-K statements or filed are information most results greater on or Factors other and forms or materially Form those XX-Q periodic implied such in our in in

for share review Lavino, Nabriva’s Q&A provide Moving to overview wrap session. XENLETA update Maria this business Francesco Slide Officer, agenda the update. a with the will financial lead will and will X, Schroeder, to launch. and on current XXXX Chief the I’d the CEO start I and Nabriva’s then today. Ted an provide will like up Commercial Ted discussion

President Jennifer In Operating addition Chief are Medical for our Schranz, to Gelone, and session Ted and Q&A Chief our Francesco, and joining call us on Officer. the the Officer; Steve

our Executive I would turn Schroeder. now Officer, Ted over like call Chief to the to

Ted Schroeder

afternoon. everyone our this and to Gary, thanks joining you, Thank call

pneumonia. XENLETA approved for August Administration significant was and Food for a a by business bacterial me and the the community and in XXXX was XXXX U.S. as Nabriva for with provide acquired of XXXX begin Let patients year treatment of a recap of Drug update.

especially to team develop Our XENLETA. and have discovered proud is

oral formulations, two With treatment and setting. home hospital it XENLETA hospitalized to antibiotic those those in the first and with for and suited and both to excited patients. physicians in in well we new action in bring use of outpatient were IV the patients, decades from the The mechanism to transitioning is initiating

to managed our large XENLETA expectations recently than of has lives at in are care this its We launched coverage formularies has that cycle well life known U.S. plans. we been and contracts point exceeded better XX% with is antibiotics. of covered other greater pleased for for in to and added than plans health place XENLETA in the all our have accounting say

most fail step require Importantly, the and at another a patient is receiving antibiotic XENLETA. requiring of prior not the coverage authorization does it or to unrestricted treatment with before

This the prescriber easier patient. the for makes and access

million coverage in with our contract continue Part XX lives. fact, manager a to recently that signed Medicare benefit represents that will expect over very covered we D a grow. pharmacy large We And

for the team has for with mechanism job with each formularies market recognition believe favorable course outstanding payers’ more need obtain new antibiotics Our done medical the an of of positioning patients treatment on a X short and speaks adult and high unmet access we the of action diagnosed to novel year. our class million a than ability to pneumonia

excellent of to their on and significantly no Based shifting In on have to copayment coverage we Connect where market coverage, Rx of time co-pay to focus sales we addition and least to $XX Nabriva patients eligible oral XENLETA. savings managed breadth sales community prescribers. XX% dedicate team for the the resources, quality force have advanced program community and than care the optimize are more our calling to at commitment our dynamics payer targeted a our the our

soon ensure we of patient one access as XENLETA sample easier and prescribes are packs the XENLETA are efforts, to as doctor the oral day To providing can ensure distribution support these enhancing to it. initiate patients

We that our on is just drive coverage the opportunity Medicare excellent that focusing product community to plans, to doctors January, our and care believe on have initiated drive pay our had we expanded to Having this near continues we managed the target new best opportunity growth. term. expected visits once expect multiple as commercial and adoption coverage improve, reps to prescription approach given in will in the coverage

that call, customer demand multiple third post of expected our for the we million $X.X quarter During earnings reflected launch. we initial ordering the said months strong

quarter. and fourth when $XXX,XXX still line approximately the the in down sales working in a initial this sales reminder, As wholesaler with expectation, product stocking, of that they're we recorded booked orders we

Launching While about XENLETA’s we care results is to space the profile. we time. formularies XENLETA and hospital timing the taking on others created for our in similar of of in IV season the still in at strategy the have hospital, for transition beginning believe were product having learning physicians fall the may issue as new a flu cat we're us a just getting

to will seasons recognizing flu a upward need awareness XENLETA trend. promote increasing we in setting, XENLETA remain that to expect hospital through we the navigating review the said, formulary sales time. consistently to takes we've see committed We of that significant As two process

XENLETA access hospitals on the XENLETA community sign as for well use providing many positive a to discharge, the adoption for believe is eventual oral of opportunity. as Importantly, which are we IV for

in CONTEPO in Nabriva We this NDA of turn CONTEPO potentially the me January XXXX. resubmitted In of established of in injection is received a year, or June and they a for to first December. for update urinary PDUFA U.S. novel action complicated date of a antibiotic resubmission NDA the IV acknowledgement XX, FDA infections. class CONTEPO. the tract let fosfomycin the on brief Now for treatment

too and CONTEPO’s year. CONTEPO. them impact to about are more that inspections are path launch providing soon the forward. Two about for announced FDA later proactively restricting days any It's we working We travel to potential information speculate forward potential they with about this look ago, to

Importantly, note resources. managing our focused we're please that prudently on

prepare launch we of near-term are ensure believe our for shareholder's to optimizing debt our We is will to in in the our maximize our that and our potential continue we Later discuss a will for performance to KPIs in the interests. XENLETA facility, CONTEPO. of presentation, which best closely Gary monitor resources restructuring all opportunity

continue X, the challenges is options We in Journal and made appeared secret. Slide the CONTEPO. Street to some available differentiated recently not the feature headwinds remain York that best a changes confident The And their antibiotics believe patients. we both certainly that legislative XENLETA enable which to Wall of will stories, to face. to highlight Times have and be the of new treatment New in we launching Moving we utilize treatments physicians Large for

public virus China infections, patients diseases to reminder with Based influenza patients most is increased health. Similar the COVID-XX COVID-XX COVID-XX the impact XX% The outbreak on secondary recent infectious to at of for have information infected an developed from up infected of pneumonia. are also bacterial available on bacterial the have pneumonia. risk

are concomitant bio immunocompromised, proactively with the Nabriva for medical efforts patients appropriate bacterial were and of BARDA promptly the considered the COVID-XX. particularly to and monitoring or secondary who should documented or Given setting We widespread the are for in in with submitted potential of preparation infection, portal. BARDA countermeasures high working viral and CABP response. have need timely organizing suspected and patients an industry administered have by treatment bacterial in brief mortality the in older, their a is via diabetes setting pneumonia empiric therapy be in closely

with coronavirus pneumonia. a suspected secondary documented as patients XENLETA offer potential treatment option in the was or infected So, bacterial

offer to addition, in to or development for acute than the Medical novel thus partner or suspected bacterial lefamulin. the China lefamulin, to even greater antibiotics macrolides for U.S. prepared pneumonia. were commercialization Administration be should the exceed with it in is Sinovant, XX%, rates the in were of EU. National treatment supporting be documented In working we need our Resistance is Products China for it needed and closely secondary more They country’s

Nabriva’s we are We developments doing mission. what and assist following to these can with closely consistent

Francesco. I turn over will the now to call

Francesco Maria Lavino

Thanks, to market. Building I’m on in the launch months progress about are everyone making the share its going on to first Ted with on and we XENLETA details afternoon Ted’s the opening, the few more good call.

the an about overlapping important wide we reminder details, Forgoing into patients variety the launch and of X are in some where settings, States three measured Slide CABP United treated the opportunities is treated inpatient the emergency patients to as or from well the community with outside are care, either outpatient directly the department hospital see. outpatient transition as in as practice. of of CABP Many

market very in from main be a fits this The with the prelaunch as care this community target on antibiotic confirmed treatment well profile the Consistent hospital. of for are IV course XENLETA discharged oral as spectrum in patients, pathogen CABP appropriate the and to with continued who initial action. a first-in-class that coverage of CABP And monotherapy month of transition XENLETA. the our view, for novel short and mechanism of a of

mentioned, But space getting to care of transition opportunity the that similar we are hospital believe results having is an and XENLETA. XENLETA from to formularies Ted important our for in is continue We taking hospital time. focus on the as IV others

We education work hospital to proposition. provide XENLETA’s the will medical continue about appropriate with to value

on a are XENLETA and revenues more continue a Despite some XENLETA. minutes, hospitals the plans work to order maximize on sign for near-term IV which to gaining our to of to community for many few our positive getting hospitals oral IV focus providing adoption access in talk strategy to we about I’ll increase on while charge, in our access the eventual IV. of formulary, of this XENLETA the for challenges In use is the

to pharmacy inventors where patient of X. their specialty for adequate and oral launch is A Slide community when has distributors secured needed. for launch XENLETA Turning Immediately, key ensuring they specialty the locations. at XENLETA been or many priority our available Walgreens their or and that after

orders has the By who our script hospital XENLETA we patient, pharmacies were has and for of retail prescription, to orders hours pharmacies. had between uptake strategy. supporting areas, side assist stock to In seen patient the are specialty those at looking an end fulfillment care than Most a XX options for transition placed agreed the some in have who XXX XXXX, in oral repeated hours. Walgreens of XENLETA more after XENLETA and of orders for

outpatient order the supporting care. community In to of the both and our channel, strengthen the in distribution transition use

direct Walgreen’s script specialty community partnership addition and fulfillment. XXXX, the for mail In we services order, care; established AcariaHealth, additional of option patient to at end the to HomeScripts provide to with

are in Publix availability continue to demand community new XENLETA and grows, look to have high proximity co-pay $XX the stocking ways a who XENLETA. Rx We more no pay expect series and placed a location program, have Nabriva want in been oral for we than with excellent Patients coverage had more will available. physician, community-based CABP, prescribing, patients Connect we close an we to expand patient eligible retail location, who see make retail volume are select will for which to for where and it pharmacies XENLETA XENLETA for collaboration in the in as with Florida, copayment

In first the patients one-day early office the the specialty also force distribution by has we sales that the sales to to their call. with community day and doctor’s our This or been with provided this and the service the leave January, script XENLETA for reps pack sample the XENLETA, pharmacy doctors of delivery fulfilled while the both only well-received allows targets. they

in transition me the on called about slide on oral target Nabriva Moving access XX. the launch hospitals either patients IV we in challenging. in hospital talk or XENLETA has space, our formulary XXX has than force as since update. end on September, have sale to the of hospital others XXX all let non-formulary with of been formulary similar hospital. getting more sales of to as the XXXX, By for XENLETA. on XENLETA care the to

a XENLETA of for is only. number of XX% P&T oral occurred review in and However, XENLETA about for access lower-than-anticipated QX

the broad be using continue but an important will to tool believe additional formulary We for inclusion. to it’s hospital to IV gain take going that time XENLETA setting,

hospitals We applied hospitals XENLETA makers C look and key been faster J granted to Code actively effective for add will target XENLETA. educate has formularies. XENLETA to decision for January Code the and for X continue will in on we status permanent

treatment as effective the of CMS J J the Code quarterly April review centers at for the Code critical granted July IV permanent Given including cycle, XENLETA C the the be if by ASP+X%. expected granted and to will the X strategy of emergency department will eventually, allows it be care if bill outpatient X. for and Code we is the new transition

XX. slide about talk coverage with the progress made managed care let on XENLETA. Moving for we’ve great to me

most from clinical access market before days done within team has the the first in after tremendous job a and launch. occurred Our launch the XX reviews

edits of than has February, life pleased XXXX, antibiotics. cycle than In prioritization. unrestricted, access our care at United are say of XXX other We the and the know to XENLETA’s in it’s expectations as that step all managed million or about management this covered point most life XENLETA. exceeded launched coverage such more recently XX% we as utilization has better accesses in of our to States or

by the Medicare a coverage major plan, added is in Aetna, about with Tricare, utilization no with Express XENLETA utilization Part lives, including cover place than Medicare Scripts, contract life primarily commercial recently we both their major management. for not D a to accounting PBM major XXX like for Anthem, management. and with commercial who have million driven of contracts commercial again, XX% and contracts have clients formularies, no signed and more have and

overage no are is both part to D Additional utilization therefore, XENLETA commercial expected and Medicare increase. with and contract, significant further management forthcoming

and community community calling we leverage to we this our will We dedicate their focus believe to payer XENLETA, order time and the the see, on us been Based significantly near-term. force optimize Moving resources slide XENLETA them asked to targeted excellent XX% dynamics the help revenues shift market we on for our for in more in of have the coverage shifting of sales have to prescribers. to XX. on driving

preparing for work approved While on and if the success gaining for on key months. access CONTEPO coming IV continue to long-term XENLETA launch formularies in for we also to the

antibiotic HCPs prescribers CABP. like These some hospital been details location. to of account high community Turning to They professional I’d in oral for share over targeted of in all our community sales November. are XX. highly force of close late to X,XXX experienced our Specialty Slide Walgreens healthcare proximity plan. targeting had targeted our since are the

e-prescribe specialty pharmacy prioritizing use for managed also are We care doctors, or call areas coverage with patient to are on prescription. high channel and our able their who

the expanded and With first to we focus in we direct the service. sales therapy, force patient pack day activated shipment patient’s breach availability of XENLETA’s to the of January assembled the also

are interaction know it the that prescribing all in once We and multiple still we in change the in before early physician takes days behavior. with

coverage prescription strategic We of number will hospital. our to to the trajectory to prescribing XENLETA for importantly, interaction CABP, initial signals multiple believe care increased given managed the and times. are to pleased focus to community We shift we see us on excellent work continue while launch number based of of the prescriber and the the allow frequency physician impact success of the access of this on

like review. now over to financial to I the the would Gary presentation turn for

Gary Sender

active On slide sheet. key Francesco. some are balance XX, our and financial slides. subsequent to we’ve these relate highlights discuss that XENLETA’s Thanks, to revenue listed I our of of relevant the position. These in will each highlights management profile

in they prescription of that expectations quarter, and Slide XENLETA approximately orders $X.X were the to initial our months call, didn’t launch. those were and the we in of post meaningful In fourth XX which multiple line demand In few our stocking. expect we and orders net net post which sales had placed with P&L. that $XXX,XXX. quarter said third we generated Turning XXXX million wholesalers sales earnings months represented

meaningful our and We recorded Chinese revenue from partnerships. also Canadian collaboration

to will progress existing other and XENLETA seek the outside patients their is products bring the continue work to we U.S. to look for opportunities We our to they forward in partners’ geographies. licensing

SG&A significantly primarily our facing to expense in expense increase the Zavante to R&D lower is the and reflects and R&D customer second that will a And in are loan facility quarter. infrastructure we with lower commercial expect the XXXX our our acquisition. given connected discuss, starting I onetime on to investments as fell in Higher interest investments Hercules. teams. be significantly trial in-process we related in for The XXXX charge in making clinical

our Cash with We our were tranche end balance XXXX the equivalents December at sheet. million the million Slide $XX approval, Post and from approximately in $XX and from million XENLETA’s cash $XX the facility in shows drew raise. key our year. $XX equity a brought through ATM of facility XX about of components million our down we XXXX Hercules. debt netted

now XX. our Slide I to debt we I interests. that facility we believe Hercules’ ask made, turn shareholders’ in decision and to which our discuss best you this is wanted

fourth of Hercules we the managing In facility we This of debt down April with on satisfy forecast. a balance quarter established them near-term million not We revenue the XXXX, proactively to certain a in of quarter achieve of the $XX balance X. if have XXXX, the risk provided to with are covenant When planned to first revenue. is outstanding sheet we decided pay million Hercules. level on occur a $XX and the we did our

in Per accessible our would create continue to have allocate with of we Hercules cash pay $X forecast parties’ loan be invest testing requirements in the and for the million We and $XX Hercules. was now business. our of balance, would down to specifically Nabriva the that utilize agreement. Post to debt pledge terms interests. therefore That million cash the only worked liquidity structure from an million had original resulting to the down to in both million and revenue will agreement, $X we a are minimum $XX performance covenant to revised collaboratively loan not updated

period will the and terms into requirement our liquidity facility. no fall the of expected is approved, XXXX. and if a agreement. eliminated that significantly expense cash as change is our down, good With as quarter interest operations standing are $X CONTEPO balance, million there fund This the the long to pay only third the Post we is debt to interest in of of Hercules our with other is

we overall lower best meant and profile believe shareholders’ our risk are that in are interest. they our again adjustments The to

we session. then head and some to will I Q&A that, With our remarks Ted? will Ted ask make closing into

Ted Schroeder

on XX, on I priorities our In want for Thanks, Gary. XXXX. to focus Slide conclusion

that and treat the by needs driven are of them. We those patients

for access to executing action utilization on by is hospitals. the possible XENLETA plan greatest as goal ensure expanding appropriate as well our community in Our

to the worked we By obtaining Medicare Part months do do several How last successfully this? managed plan on D has care what particularly for patients. expanding over coverage,

We of a with a the appropriate risk CAP, demand expect for targeted interactions increase to education as particularly patients. the them to frequency antibiotic continue option we for treatment XENLETA benefits see with the physicians, providing high like novel as having about growing of

launch our demand, also expand XENLETA. Linked knowledge to the to XENLETA we growing to of position will potentially Leveraging oral work with strengthen we retail and relationships prescription gained availability will CONTEPO.

expect We the medical the XENLETA benefit year and of unmet have and in half a approval the geographies to high to patients see Europe in second Canada of those need. who

offerings. We’ll continue out-licensing resources opportunities that XENLETA the growth we opportunistic look sheet risks infrastructure, balance In of and managing U.S. thoughtfully might both as and create community. in-licensing to both reduce look for Nabriva our business fit development assets strategically product the hospital as to in the our outside while by for parallel, to the well being

Finally, consistent that bacterial by everyone secondary who please to Doing so track patients Nabriva at know with standing can company assist our mission. pneumonia. is COVID-XX is

to lines I the operator open questions. the would like for to Operator? ask now

you call? Operator, are the on

Operator

apologize, first Our Instructions] question of Lebowitz comes Morgan [Operator David from I mute. was I on Stanley.

Your line is open.

David Lebowitz

shift this how the our Given forward, consider sales we projections? sales in strategy going in should

Ted Schroeder

David, I’m mean, projections. sales what consider should your not we you how in exactly sure

David Lebowitz

think I I with ramp? the mean, respect to

Ted Schroeder

so, yes. ramp, the For

Okay.

So thanks David. for question, the

you have ramp with the we that I interactions about number really think of the physicians. by for the ramp the community think is driven as

community, you’re for going great and on through side, track important and formulary process is managed Medicare care in It’s community-acquired who hospital pharmacy can we Part the And review lengthy patients coverage. which improving so the particularly pneumonia. older have where D the a unlike therapeutics

to it to change interactions of a prescriber. so six is of physician’s standard seven the takes And with kind that that kind start behavior or get

we’re to so we And that ramp. in January; starting started see giving,

as to will that grow over those interactions year that ramp expect We the up. continue

necessary would So it we’re see think we right helpful? now. of prescription. bits to I do takes as to quarter, two the seasons we get fill end the together get all that reiterate front that first guidance sales the previous it and that are the a at increases meaningful in But flu that in Is as second our we pieces through quarter,

David Lebowitz

Yes, Would guess, sale coming from I the will affect in in transition away, oral it hospital year? shifting the guess that use, that term you that is. a the say near the of, I the IV in to protections

Ted Schroeder

because hospitals in we It Francesco improve sales other the antibiotics. as should projections as actually as process has with explained, seen formulary hospital the been slow

the had more utilization community, focus made strategic the because we access XENLETA positioning, in we that greater so to drive managed the is given care And best the in the community. that to effort decision excellent way for

We’re within budget of to advocates multiple are make not where hospital where hospitals the opportunity community abandoning the XENLETA. the efforts our the of to kind timing opportunity constraints the approval bigger hospital, intentionally we working sure that down for slowing but that’s the product pivoted an of – have that we for prescribing and in we’re XENLETA. we’ll drive we really is have for That’s because to earlier have and

David Lebowitz

for Thanks questions. my answering

Ted Schroeder

you Hey, Thanks. bet.

Operator

question & The Carr Alan of comes from Needham Co. next

Your line is open.

Alan Carr

Hi. taking Thanks questions. for my

Ted Schroeder

Hi, there, Alan.

Alan Carr

your comment you’ve missed internal based debt on your, if had a projection guess, your in So you expectations that covenant. I

guess So in the but you two go could and through miss internal have drove what, maybe mentioned it expectations your do seasons, financial what flu constraints. you I takes you

get trajectory there this and about year how a for can strategy in realistic So talk and what’s you can change you sales. what’s Thanks. meaningful to your the

Ted Schroeder

for standard with rock that’s on But primarily responsible the we as steep up ourselves with the And we XXXX the to know, could’ve forecast reason kept quick found the plan a big advantage exactly We stayed And – the community. to could’ve Alan. the and us. of in Thanks, that’s made opportunities this early pivot where game hill. pushing It’s really you take and Hercules. Yes. with hospital. for our a that’s of front

to team. the of excellent And to our managed But such care expect quick didn’t we – prelaunch. markets managed so efforts adoption have the thanks

and not have that’s better without adoption, only but formulary, than restrictions expected an important formulary We differentiator.

to get have We’re the wait prescription not to having – patients filled.

at to the prescription imagine the having As an for antibiotic you a pharmacy. patient that’s fill gating can

fishing the it’s fish So where of little bit are. a

drive the allow the was of us to think opportunity catch opportunity. to bigger only performance strategy can oral pull the come from we’ve the community. care do always a leaders community believed actually as push care But we’ve that a we both it to from that accelerate the not understand managed but setting. access was of We’ve seen transition a improve, that thought really community up, the XENLETA. into will and So we The

pull prescribing push and hospitals, discharge at into same the through patients So to into retail those the community. physicians back

Alan Carr

back get have guess aspect you there? hospital I in a may percentage even do the bit had this the of other extent expect much have target to slower than an go key that more is is success Medicare of you the is way and in sooner have the you fair do thought, coverage help. So you what language of that community what imagine opportunity then, way then, had and into to expected, lives? the through then you but base of do move which you than to patient that a on you Because are there? all when what How there, to coverage But terms

Ted Schroeder

thanks. Yes,

answer So bit hand Medicare detail. I’m Francesco about more to off and start coverage that Alan question let provide a the going it to to me

gating front in basically of make D As six the the decision items you end. have for is know, months Part Medicare one to they a

said on million we earlier months six signed XX contract so call that basically is that with now the plans. that And lives. We so the contracting process of we’re come doing the covers in up and the just the just

kind to a runway. of up getting we’re so And

We D have sign other a that with to in the Part we’re expecting number future. of relative near contracts Medicare

And classes, D in faster most kind Part other perspective, put in Medicare in products some products, other that you a with moving experience are been market actually my still around for of have look in So products in actually other digits low-double the that the coverage. we’re dealing for while, do. with companies Medicare are therapeutic on and there if

we expect the that past be will that We during year. moving

early So you care that a our our continue add want Francesco, will – coverage greater managed that say the we but have to need agree I it’s to that to conversations year. indicate throughout if there… improve coverage, I’d Medicare gating,

Francesco Maria Lavino

first Ted for Yes. mean have said, what so the Alan, mean I I question. we to all, thanks be of signed just contract.

it but major couple again, the a while a of plans. review, signed contracts took with we of So six months because

it’s now plan contract to putting the XENLETA stop of So, a matter been on various the had but signed. formulary,

couple a of months, increase coverage the lot. will Medicare Part D we so And expected over next

the the XX% we prior hand, all are other all there have are I they we patients the to commercial, commercial again, we the covered I there, very formulary with majority wanted but seeing patient today. On I eventually come actually majority And commercial mean from mean that mention, the also agree, specific would are patient that population of on to of once XENLETA close no the lives, have authorization. with also

because So signed. been the Medicare Part contracts up, D come is coming. It’s will already good. had It

formulary. different plans contract, Medicare these they prior drug again, just with is of told to now put it’s good on even the no And the thing the a So that authorization. matter have

months. over a And really will lot of so coverage we the improve that expect next couple

takes doctors to especially change parallel, really interaction it the with to In Ted community, what the behavior. to see comes in it when multiple was saying,

as physician into we the D we have quarter, frequency believe so get will the that on And interaction we on Medicare really and second with side of coverage, the the one especially increased there. the Part hand

of ramp up should going so up. prescription see the really And we

Ted Schroeder

at me point. let covered have just coverage acquired a point is five-day is When macrolides Alan, for the here which patient ideal. work. out then really important is not treatment of the other pneumonia that get you back were of we XX% indication think this courses significant. the for course keeps commercial lives two and of them two Yes. work day weeks XENLETA for five is The of single to add I with community that that a and treating patient that Giving one can commercial for prescribe patient

It’s things from have actually of of jobs, to time for who of number that that One plans have looking seen than a health days by sick. the sure when patients, some a on the of don’t more available actually with couple at their you’ve recently population they’re academics a light U.S. paid the off them. portion covered sizable shine sick

back So gets the Medicare that that one is look on real favorably I a patients. patient reasons – actually in week in adopting believe And XENLETA short therapy the those in to a and of addition to five work – that to physicians benefit the will well population population. course within within a

Alan Carr

Thanks questions. for taking my

Ted Schroeder

Alan, thank that, you. With

Operator

of comes Bank Our next question Gerberry from America. of Jason

Your line open. is

Unidentified Analyst

point now to communications those guess, potentially for talk physicians, when follow what analog hospital, beat This evening. the an there’s the guess, community Thank how for Hey, you. seems hospital that me good can to that taking I care. can oral Good can behavior. second if in by of a Jason that community community a question think will transition maybe in do kind of is of and you’ve friend, there I back about or maybe the they any a questions. setting, sort more And focus use. my the through leaders Gerberry. talk would pivot we they on analog guess, a of route there’s to afternoon. thought follow. the an I pivot can if to will passing going you just of – what follow [indiscernible] guess, that Ted, to I for prescriber with you change of went for prescribers a Thanks see the it would prescribers. to to want we KOL. like They be, start similar of I that trajectory hospital lot analog community that that our antibiotics

Ted Schroeder

question. the Sure. Thanks. Appreciate

that, will quite the the an piece. treatment community been there’s I both hospital been think kind back drive prescribing like, pneumonia. analogs and are analogs. have an it’s IV – the an the community look what and do summarize oral of acquired a question, It for look to awhile what So both levaquin we analog of in moxifloxacin said since there? think kind unfortunately, and And there’s broader to you’d earlier community a for that’s to quinolones,

that, but markets they’re were tissue there various there’ve products haven’t entering had entering that, of crowded they I the and – that time. Short been, skin some of soft been at iterations mean, really

back think Those really really quinolones products probably driven introduction by way probably the community mainly the the to prescribing. respiratory large all analogs. best it’s are the I So of became

the that’s pneumonia in KOL it’s acquired But the community, a specialists. more influence It’s conditions. – standpoint, not you internal treatment From are And patients hospitalists physicians, in understanding really patients disease driven But more typically of in not department by of in emergency see physicians. pulmonologists the hospital, it’s an and decision. type an a a complicated treated of physician. community care urgent that’s that condition infectious treat is true really really it’s the lot front the medicine who and of KOL by

surveillance some closely that we’re other strep for look programs. in cause example, pneumonia zip to working the with the And trends resistance down at we’re actually pneumonia we acquired for have code The is tool to leading level. is areas, able of which community

for adopt for they down strep rates it XX% number where product willingness area, And meaningful and hard impact between resistance, and and That their to they’ve bring XX%, national their a live shown as focus days. a that on. treat and in patients a can can do reliably you their has it U.S., But we’ve see it’s local to that’s see XX%, to five patients XX% on in when a physicians the pneumo. XX%. But discussed we physicians and that’s resistance generally before,

busy So actually XENLETA we primary of attractive think the strength are physicians. care oral very to

Gary Sender

not XENLETA why, reason many are, experience clearly discharge quite – situation, some the sending in hospital. said, of we hospitals might treatment the we I where IV on value said, as yet bring as to consistently the but the for outside to I can for appreciating everybody hospital. But And add the the or the formulary, yet if laser the is not might have might really that of patient the XENLETA add same it can that, use as outside the we zone IV want kind That’s heading to they’re hospital. the in they mean, others of

population people the outside is So of of in clear clear community of, this in has proposition. also but very value as everybody’s that a way, aware a very is Ted a really drug problem hospital that very a mean hospital think said, certain patient that there’s resistance strong that I the

the well. from hospital as influence some expect still into will community we So the

Unidentified Analyst

Thanks. Maybe another question Gary. if I maybe for

about potential development. can BD you So, talk

today's volatility thinking seen can in of cash pull and auto beyond it's you I'm for talk kind curious what about Just market. XQ you Can development about levers are BD with rate run Thanks. XXXX?

Francesco Maria Lavino

Yes.

opportunities the So to de-risked we our That's our balance maybe as fund the all past guidance we company. significantly can for runway talk obviously. sheet. will look about cash in revised And

have think bringing the non-dilutive into funding record of a I we in company. track

unmet to opportunities the and to know, in as that, the on on you financing. could hope Europe And have opportunities a we to in in and to for past, a expect development in be other fund an pneumonia beyond we year. as on at bring geographies we There's decision have, some And in file, half large have back – well. we business that that Europe all other in transaction company. hear medical need able the patients non-dilutive MAA We consistent have will Europe in second look the of we

Unidentified Analyst

you. Thank Okay.

Operator

Instructions] [Operator from comes Kevin Kedra next of Our question G.Research.

is line Your open.

Kevin Kedra

taking for answer pretty I this be think it relevant. know but Thanks question, it's might to early my questions. I

anticipate environment? next over do playing quarters? this coronavirus, there would be how the a get – you you kind doctor You least But still engage that of times in in able out front helpful? world or doctors you in seven maybe six the add a social what's as with habits. to At the prescribing you on going to mentioned can do relative in we're being to approaching of to see several have of Anything distancing that influence with order to

Ted Schroeder

Yes.

early right, days campuses, on medical to where brings some fairly are at trying So, facing and certainly reported it's hospital examples think, it's major an to early We've the to just where to at of question, employees. been really patient centers restrict we're trying us. excellent kind seen employees understand their access still you're they've that and level. They widely

even non-patient interact they're with so are And interacts, they working remotely. pay – don't that employees patients

hospital other continue help We've of means if physicians And been efforts that and have So that the there's seen number message those introduced physician support the side, the non-personal And already the we through that established a it's are been you on there to prescribers. electronic support on for to and Francesca actually want in preparing XENLETA work already high can impact believe that to we we're but and add? side. some will oral through of details of less those use that. some

Francesco Maria Lavino

clearly as long ready phase mean, to face restriction too I getting access. to said, we not I up potentially, are hopefully face No, mean Yes. to of Ted time a a

and So, we have we campaign, will already even a clearly digital be further housing considering that. planned way that in multichannel

front plays in we started definitely customers leveraging in to any message, forward. will are more – and of touch with. to be engaging and moving remotely that we'll deliver probably But have continue especially already So get our we to have the means we those plenty

Kevin Kedra

the young of what to voice area supportive that an pneumonia. can lot is in I guess, an role that there Mentioned people with secondary COVID-XX you that. providing a different you're kind can active guys in appreciate to outbreak How heard of in care the right play guys with ensure make for Great. for and that your role voices, I – of a supportive and there's XENLETA in care? level people of that of kind lot you as things. a of do front there's playing you

Ted Schroeder

Yes.

that a policy – and the larger think I'll ask there's just of can right? of then others general Jalon I and the be side Steve it's that disease. multilayered Gelone there's kind BARDA driven places like actually on questions the through that question, comment that and There's knowledge a So

fact that infections secondary is also The regular secondary to COVID-XX. novel the degree are seasonal there that's one influenza things I bacterial of bacterial a not infections. think that are high in our the of has favor

reasons of patients, One that at infection. antibiotics for outcomes older, we more particularly season isn't have the secondary flu – a during That risk up why they news. are doesn't, when for new because bacterial CABP sicker see is patients

policymakers, treating to the think news, new physician. new but news the sometimes not it's I it's

Staph. treated resistant broadly so with its multidrug the and and therapy foremost multidrug organisms XENLETA activity being course And including advantages pneumonia against first is strep short the of and resistant

more, in you see efforts. I will opportunistic if XENLETA And as will and you’re recognizing the has infections, we to to where in China, I think if experience in we a to more promotional of and actual with remarkable kind attention broad in grow close XX%. the more you education more an infections XENLETA group antibiotics If used so want profile policy era, in more that continue rate’s more to sicker to a see really the profile of And so And see anything – own our related its from which about having population, going see a to comment pneumonia. treat around that, efforts. Steve, opportunities? think you organically on group do antimicrobial come

Steve Gelone

our for interacting information I lefamulin and we approach we’ve thanks to it’s the and them the it think voices about asking may have remarks, the a you our where obviously role. multipronged was mentioned provided prepared with of on and get around how some to during proactively the Yes, been as a BARDA yes side dialogue. ensure Sure, kind were what in question. front of play

last well last early just agency now as days, to that BARDA’s activities with has a kind days, others also their coordinate so leg if related COVID-XX. bio and involved BARDA on broader they’re industry with resistance group to the of the antibiotic development of working trying space. will, time with stool released the influence announcement the COVID-XX. is around you four in is in around three this the or the doing working third of effort We’re and that broad It’s try of then wide part effort in to that what And lobbying been I piece the need long we’ve for antibiotic a and things antibiotic for guess

medical even to into are are we for unmet think ensure a to that And an used that because dollars with for that don’t highly but been treatments so areas a China be as and towards where from generic there and recognition that that bacterial made to lot where need, is the spending that outlaid country, that places and than needed, proactively situation, relates was effected, engaged be have trying products available, are that supply point wind get the are older diagnostics, direct think, the to that continue the in APIs ammonia are time people in eight billion therapies chains India, is which they antivirals Recognizing no particular whatever to directed will it fact some acting and obviously of COVID-XX. so up as their and we’ll have – U.S. long vaccines a of there energy rooted because of in are allocated more we appropriations time most they’re able are I not like a in I the

So, I in be approach the think, to proactive continue and that’s it. will taken we’ve

Kevin Kedra

seem have taken extra quarter actions kind company been thinking dilutive more an at to given cash you cold of – sort to debt and some Great. we’re that that there, Thanks. a financing? taken flu seem XXXX, think loan, to quite still actions of down of doesn’t should of you’re have of Gary, some or one still A is to to we very I environment one. possible surface do for cash least in antibiotic be paying that an the be you the to conditions in into QX for Hercules season, valuable be flow? get given it in peers – that market have. or Last about the your do would markets the next buy time to you some good know cash on of two mentioned How into the you now, but – it a you, is do very the the to get opportunities and tap see highly

Ted Schroeder

– Kevin. I Yes, can’t it’s mean, speculate. really we

cash we’ve shown shareholders’ all look what we But you speculate that I’m we’ll we’re on best And company. beyond that. the think our interests. into I to can’t about we’ve As actions the sure really that think can take at appreciate, before, bring we opportunities past mentioned will going we do. done that in that, we’ve And to

Kevin Kedra

right. Thanks. All

Ted Schroeder

questions on the more any line? Operator,

Operator

no further am this time. showing questions you may I Presenters, at continue.

Ted Schroeder

we interest, Thank as forward your you we’ll to questions, focus and we talk progress XENLETA soon. the you for make community your for continue everyone community-acquired pneumonia. treatment of our and thanks Well, Okay. to look for on updating

Operator

this a concludes gentlemen, conference. day. for have your and you and wonderful today’s Thank Ladies participation

all may You disconnect.

Nabriva Therapeutics (NBRVF) 12 Mar 202019 Q4 Earnings call transcript